These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33140519)

  • 61. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
    Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
    Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Exploratory Economic Evaluation of Buprenorphine Treatment in Opioid Use Disorder.
    Elarabi HF; Al Ghaferi H; Hasan N; Lee AJ; Shawky M; Al Kathiri H; Elrasheed A; Al Maamari S; Gawad TA; Radwan D; Adem A; Marsden J
    J Ment Health Policy Econ; 2021 Sep; 24(3):89-95. PubMed ID: 34554106
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Characteristics and experiences of buprenorphine-naloxone use among polysubstance users.
    Walker R; Logan TK; Chipley QT; Miller J
    Am J Drug Alcohol Abuse; 2018; 44(6):595-603. PubMed ID: 29693427
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Naloxone Deserts in NJ Cities: Sociodemographic Factors Which May Impact Retail Pharmacy Naloxone Availability.
    Lozo KW; Nelson LS; Ramdin C; Calello DP
    J Med Toxicol; 2019 Apr; 15(2):108-111. PubMed ID: 30805884
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Factors associated with naloxone availability and dispensing through Michigan's pharmacy standing order.
    Dahlem CH; Myers M; Goldstick J; Stevenson JG; Gray G; Rockhill S; Dora-Laskey A; Kellenberg J; Brummett CM; Kocher KE
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):454-463. PubMed ID: 35405078
    [No Abstract]   [Full Text] [Related]  

  • 67. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
    Tutag Lehr V; Nolan C
    J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of opioid dependence with buprenorphine: current update.
    Soyka M
    Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Naloxone Availability in Retail Pharmacies and Neighborhood Inequities in Access.
    Egan KL; Foster SE; Knudsen AN; Lee JGL
    Am J Prev Med; 2020 May; 58(5):699-702. PubMed ID: 32005590
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
    Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P
    J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
    Ostrach B; Potter R; Wilson CG; Carpenter D
    J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Readiness of community pharmacies to implement an opioid safety intervention.
    Floyd AS; Silcox J; Cousin E; Irwin AN; Gray M; Bolivar D; Bratberg J; Arnold J; Al-Jammali Z; Hansen RN; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(1):275-283.e1. PubMed ID: 36496310
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City.
    Marotta PL; Abbas BT; Stringer K; Huang D; Schnaidt J; Goddard-Eckrich D; El-Bassel N; Gilbert L
    Int J Drug Policy; 2021 Nov; 97():103321. PubMed ID: 34358803
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
    Pollini RA; Joyce R; Ozga-Hess JE; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2020; 60(6):853-860. PubMed ID: 32651116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.